CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

When, where, and how to target vascular inflammation in the post-CANTOS era? Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Percutaneous Coronary Intervention for Chronic Total Occlusion—The Michigan Experience: Insights From the BMC2 Registry Informed Shared Decisions for Patients with Aortic Stenosis Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention 2019 ACC/AHA/ASE Advanced Training Statement on Echocardiography (Revision of the 2003 ACC/AHA Clinical Competence Statement on Echocardiography): A Report of the ACC Competency Management Committee

Editorial2019 Aug 7;40(30):2492-2494.

JOURNAL:Eur Heart J. Article Link

When, where, and how to target vascular inflammation in the post-CANTOS era?

Maffia P, Guzik TJ. Keywords: atherosclerosis; target vascular inflammation; CANTOS trial; secondary prevention; history of myocardidal infarction; IL-1 pathway

LINK


This editorial refers to ‘Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis’, by A. Vrommanetal., doi:10.1093/eurheartj/ehz008